Monthly Archives: June 2022

AUTOWEB, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws;…

Posted: June 5, 2022 at 1:58 am

Item 1.01 Entry Into a Material Definitive Agreement.

On May 26, 2022, AutoWeb, Inc. ("Company") entered into a Fourth Amendment toLoan, Security and Guarantee Agreement ("Credit Facility Fourth Amendment") withCIT Northbridge Credit LLC ("CNC") to amend the Company's existing Loan,Security and Guarantee Agreement with CNC initially entered into on March 26,2020, as amended on May 18, 2020, July 30, 2021, and September 13, 2021 (theexisting Loan Agreement, as amended to date, is referred to herein collectivelyas the "Credit Facility Agreement").

The Credit Facility Fourth Amendment provides for (i) a reduction in the minimumborrowing usage requirement from forty percent (40%) to twenty percent (20%) ofthe aggregate revolver commitments under the Credit Facility Agreement, whichresults in a reduction in the minimum borrowing usage requirement from $8.0million to $4.0 million; (ii) a reduction in the base amount used to calculatethe underusage fee from $10.0 million to $6.0 million; and (iii) application ofthe approximately $4.0 million in the Company's restricted cash account used ascollateral under the Credit Facility Agreement to reduce the current outstandingloan balance under the Credit Facility Agreement by this amount.

The Credit Facility Fourth Amendment also amends the Credit Facility Agreementto allow the financing of insurance premiums for the 2022-2023 renewal periodunder the Credit Facility Agreement and that any liens on the associatedinsurance policies or proceeds thereof that secure the financing of theinsurance premiums shall be permitted liens.

The foregoing description of the Credit Facility Agreement and Credit FacilityFourth Amendment is not complete and is qualified in its entirety by referenceto the Loan, Security and Guarantee Agreement dated as of March 26, 2020, by andbetween the Company and CIT Northbridge Credit LLC, which is incorporated hereinby reference to Exhibit 10.1 to the Current Report on Form 8-K filed withthe SEC on March 26, 2020 (SEC File No. 001-34761), as amended by the FirstAmendment to Loan, Security and Guarantee Agreement dated as of May 18, 2020,which is incorporated herein by reference to Exhibit 10.1 to the CurrentReport on Form 8-K filed with the SEC on May 19, 2020 (SEC File No. 001-34761),the Second Amendment to and Consent Under Loan, Security and Guarantee Agreementdated as of July 30, 2021, which is incorporated herein by reference to

Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on August2, 2021 (SEC File No. 001-34761), the Third Amendment to Loan, Security andGuarantee Agreement, dated as of September 13, 2021, which is incorporatedherein by reference to Exhibit 10.1 to the Current Report on Form 8-K filedwith the SEC on September 15, 2021 (SEC File No. 001-34761), and the FourthAmendment to Loan, Security and Guarantee Agreement, a copy of which is filed asExhibit 10.1 to this Current Report on Form 8-K and is hereby incorporated byreference.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

On May 27, 2022, Michael A. Carpenter notified the Chairman of the Board ofDirectors ("Board") of the Company that, effective immediately, he was resigninghis position as a member of the Board and as a member of the Board's AuditCommittee ("Audit Committee").

Mr. Carpenter was a member of the Board's Audit Committee. Mr. Michael J. Fuchshas been appointed by the Board to serve as a member of the Audit Committee toreplace Mr. Carpenter.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On June 1, 2022, the Board approved an amendment ("Bylaw Amendment No. 2") toSection 3.02 of the Company's Seventh Amended and Restated Bylaws ("Bylaws") todecrease the number of authorized directors on the Board from eight (8) to five(5) members. Bylaw Amendment No. 2 will be effective upon expiration of the termof the Board's Class III Directors upon commencement of the 2022 Annual Meetingof Stockholders ("Effective Time"). Bylaw Amendment No. 2 supersedes AmendmentNo. 1 to the Bylaws that was previously reported and that was to be effective asof the Effective Time to reduce the number of authorized directors of theCompany from eight (8) to seven (7).

Item 9.01 Financial Statements and Exhibits.

--------------------------------------------------------------------------------

Edgar Online, source Glimpses

Go here to see the original:
AUTOWEB, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws;...

Posted in Fourth Amendment | Comments Off on AUTOWEB, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws;…

Genetic paparazzi are right around the corner, and courts arent ready to confront the legal quagmire of DNA theft – ThePrint

Posted: at 1:58 am

College Park/Atlanta (US), Jun 5 (The Conversation) Every so often stories of genetic theft, or extreme precautions taken to avoid it, make headline news. So it was with a picture of French President Emmanuel Macron and Russian President Vladimir Putin sitting at opposite ends of a very long table after Macron declined to take a Russian PCR COVID-19 test.

Many speculated that Macron refused due to security concerns that the Russians would take and use his DNA for nefarious purposes. German Chancellor Olaf Scholz similarly refused to take a Russian PCR COVID-19 test.

While these concerns may seem relatively new, pop star celebrity Madonna has been raising alarm bells about the potential for nonconsensual, surreptitious collection and testing of DNA for over a decade. She has hired cleaning crews to sterilize her dressing rooms after concerts and requires her own new toilet seats at each stop of her tours.

At first, Madonna was ridiculed for having DNA paranoia. But as more advanced, faster and cheaper genetic technologies have reached the consumer realm, these concerns seem not only reasonable, but justified.

We are law professors who study how emerging technologies like genetic sequencing are regulated. We believe that growing public interest in genetics has increased the likelihood that genetic paparazzi with DNA collection kits may soon become as ubiquitous as ones with cameras.

While courts have for the most part managed to evade dealing with the complexities of surreptitious DNA collection and testing of public figures, they wont be able to avoid dealing with it for much longer. And when they do, they are going to run squarely into the limitations of existing legal frameworks when it comes to genetics.

Genetic information troves You leave your DNA behind you everywhere you go. The strands of hair, fingernails, dead skin and saliva you shed as you move through your day are all collectible trails of DNA.

Genetic analysis can reveal not only personal information, such as existing health conditions or risk for developing certain diseases, but also core aspects of a persons identity, such as their ancestry and the potential traits of their future children. In addition, as genetic technologies continue to evolve, fears about using surreptitiously collected genetic material for reproductive purposes via in vitro gametogenesis become more than just paranoia.

Ultimately, taking an individauls genetic material and information without their consent is an intrusion into a legal domain that is still considered deeply personal. Despite this, there are few laws protecting the interests of individuals regarding their genetic material and information.

Existing legal frameworks When disputes involving genetic theft from public figures inevitably reach the courtroom, judges will need to confront fundamental questions about how genetics relates to personhood and identity, property, health and disease, intellectual property and reproductive rights. Such questions have already been raised in cases involving the use of genetics in law enforcement, the patentability of DNA and ownership of discarded genetic materials.

In each of these cases, courts focused on only one dimension of genetics, such as privacy rights or the value of genetic information for biomedical research. But this limited approach disregards other aspects, such as the privacy of family members with shared genetics, or property and identity interests someone may have in genetic material discarded as part of a medical procedure.

In the case of genetic paparazzi, courts will presumably try to fit complex questions about genetics into the legal framework of privacy rights because this is how they have approached other intrusions into the lives of public figures in the past.

Modern US privacy law is a complex web of state and federal regulations governing how information can be acquired, accessed, stored and used. The right to privacy is limited by First Amendment protections on the freedom of speech and press, as well as Fourth Amendment prohibitions on unreasonable searches and seizure. Public figures face further restrictions on their privacy rights because they are objects of legitimate public interest. On the other hand, they also have publicity rights that control the commercial value of their unique personally identifying traits.

People whose genetic material has been taken without their consent may also raise a claim of conversion that their property has been interfered with and lost. Courts in Florida are currently considering a conversion claim in a private dispute where the former CEO of Marvel Entertainment and his wife accused a millionaire businessman of stealing their DNA to prove that they were slandering him through a hate-mail campaign. This approach replaces the narrow legal framework of privacy with an even narrower framework of property, reducing genetics to an object that someone possesses.

What the future may hold Under existing laws and the current state of genetic technology, most people dont need to worry about surreptitious collection and use of genetic material in the way that public figures might. But genetic paparazzi cases will likely play an important role in determining what rights everyone else will or will not have.

The US Supreme Court is very unlikely to recognise new rights, or even affirm previously recognized rights, that are not explicitly mentioned in the Constitution. Therefore, at least at the federal level, individual protections for genetic material and information are not likely to adapt to changing times.

This means that cases involving genetics are likely to fall within the purview of state legislatures and courts. But none of the states have adequately grappled with the complexities of genetic legal claims. Even in states with laws specifically designed to protect genetic privacy, regulations cover only a narrow range of genetic interests. Some laws, for example, may prohibit disclosure of genetic information, but not collection.

For better or for worse, how the courts rule in genetic paparazzi cases will shape how society thinks about genetic privacy and about individual rights regarding genetics more broadly. (The Conversation) NSA

This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.

Continued here:
Genetic paparazzi are right around the corner, and courts arent ready to confront the legal quagmire of DNA theft - ThePrint

Posted in Fourth Amendment | Comments Off on Genetic paparazzi are right around the corner, and courts arent ready to confront the legal quagmire of DNA theft – ThePrint

Abide by the checks and balances of law enforcement | Mint – Mint

Posted: at 1:58 am

In the fall of 1991, Agent William Elliott of the US Department of the Interior began to suspect that Danny Kyllo was growing marijuana at home in Florence, Oregon. But mere suspicion was not going to get him very far. For Kyllo to be brought to justice, his house had to be physically searched, and no judge was going to issue a warrant on the basis of a hunch. Which is why, on 16 January 1992, Elliott pointed a thermal imager at Danny Kyllos home, and, having detected heat signatures consistent with the sort of high-intensity hallide lamps used for indoor marijuana cultivation, the agent was able to convince a judge to issue a warrant. Kyllo was arrested and indicted on a federal drug charge. Once in court, Kyllo moved to suppress the evidence that had been seized from his home. The thermal scan, he argued, was a violation of his Fourth Amendment Right against unreasonable search and all evidence flowing from that was the fruit of a poisoned tree. He had an expectation of privacy within his home and it didnt matter that the government had not set a foot inside to obtain the initial evidencetheir use of thermal imaging technology from afar was as much of an intrusion as an actual break-in.

That case went all the way up to the US Supreme Court, which, in a split (5-4) decision, ruled in favour of Kyllo. If the government uses a device that is not in general public use (such as thermal-imagers at the time) to explore details of a private home that were previously unknowable without physical intrusion, Americas apex court held, such surveillance would be a Fourth Amendment search" that could not be conducted without a warrant.

To the layman, this decision might seem surprising. If our objective is to bring criminals to book, does it really matter how we go about it? Isnt growing marijuana a crime? If so, how does it really matter if evidence of the commission of this crime was obtained using remote scanning technology?

It is important to remind ourselves that the state has a monopoly over the use of violence. It is, therefore, important to ensure that the exercise of state power is always subject to appropriate checks and balances. Failure to do so would make victims out of innocent citizens, and this, in our modern conceptualization of the states role, is unacceptable.

There is probably no situation where the stakes are greater than in a criminal investigation. It is here that the state machinery is under the greatest pressure to deliver criminals to justice, and where, as a result, either accidentally or with calculated disregard, the rights of the innocent are most likely to be trampled upon. Therefore, it is here that checks and balances are most important.

When these restrictions are applied, law enforcers are constrained in what they can do to bring criminals to justice. As a result, some law-breakers will inevitably get away. We need to recognize that this will happen, and accept it for what it is, because the alternative would be to have innocent bystanders subject to egregious intrusions at the hands of the stateand that is far, far worse.

India does not apply the concept of due process in exactly the same way as the US does, but the underlying principlethat the power of the state must always be subject to reasonable restrictionsis well established in Indian jurisprudence. When the Indian Supreme Court held that mandatory linkage of Aadhaar numbers to our bank accounts was disproportional exercise of state power, it pointed out that [U]nder the garb of prevention of money laundering or black money, there cannot be such a sweeping provision which targets every resident of the country as a suspicious person." And yet, despite decisions like this, we need look no further than the morning papers to see restraints on state power flagrantly violatedoften on a daily basis, unfortunately.

Technology exacerbates the problem. Almost always, new technologies are more pervasive than the ones that preceded it. They make what was previously impossible relatively trivial to carry out, often at a much larger scale than before. If we allow the state to use technology in the exercise of its power and fail to impose checks and balances properly tailored to the harms these new technologies could cause, the innocent will inevitably suffer.

We are seeing this play out in the context of online messaging services, where the states desire to intercept messages exchanged between criminal elements is pushing the government to remove the protection that end-to-end encryption offers. The state maintains that it has no option but to intervene in this manner; criminals have no constraint on what technology they can or cannot use and if law enforcement agencies are forced to fight them with hands tied behind their backs, the bad guys will win.

Not only is this approach constitutionally unsustainable, it is downright lazy. Advances in technology have always made it easier for criminals to stay ahead of the law. But the response of law enforcement must never be to weaken the checks and balances under which law enforcers are legally constrained to operate. Basic principles require as much. Instead, they must work to get up to speed with the new technology in question, develop novel investigative techniques that work within the new paradigm we all find ourselves in, and find ways to catch criminals in spite of any technological advantage they might have.

As impossible as this might seem, I know it is possible. Because we have done this before and can do it again.

Rahul Matthan is a partner at Trilegal and also has a podcast by the name Ex Machina. His Twitter handle is @matthan

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Read more from the original source:
Abide by the checks and balances of law enforcement | Mint - Mint

Posted in Fourth Amendment | Comments Off on Abide by the checks and balances of law enforcement | Mint – Mint

We Own This City review: Spiritual follow-up to The Wire exposes a failure of policing and public policy – Entertainment News , Firstpost – Firstpost

Posted: at 1:58 am

We Own This City takes nonlinear storytelling to an extreme, but once you get on its wavelength it rewards your patience.

Language: English

The truth about Baltimores systemic dysfunction has always been stranger, uglier and knottier than fiction. Reading about its drug, homicide, policing and administrative problems can take you into a rabbit hole you cant get out of. The bleak reality of the city shaped five seasons ofThe Wire, which remains one of the most incisive feats in longform storytelling on TV. David Simon, theBaltimore Sunreporter who was the creator of the HBO series, returns to the corners, the streets and the police precincts to sound another warning about a system in paralysis.

Baltimore stays on as the lead character in Simons new miniseries,We Own This City. Epitomising the incurable malady afflicting the city this time around is the Gun Trace Task Force (GTTF), an elite Baltimore Police Department (BPD) unit tasked with getting guns and drugs off the street. The reality was far different: these officers pocketed the money during seizures, sold stolen drugs, planted evidence, robbed law-abiding citizens, and made overtime claims for unworked hours. The reign of terror ended with federal indictments, with eight members sentenced to prison. The GTTFs blatant abuse of power was the subject of Baltimore Sun journalist Justin Fentons book,We Own This City: A True Story of Crime, Cops, and Corruption, and now its adaptation by Simon and frequent collaborator George Pelecanos.

The show presents a demoralising account of how the publics trust in the police, the elected officials and the government is destroyed when those meant to protect and serve are the very ones habitually violating peoples constitutional rights. Whats worse is the establishment continued to protect and serve these rogue policemen, despite repeated complaints filed by the apprehended criminals and the general public. To trace the rise and the fall of the GTTF, the episodes cover a time period from 2003 to 2017 to draw the whole picture.

Jon Bernthal as Wayne Jenkins

Director Reinaldo Marcus Green, who is coming off the recent success of King Richard, shines a light on how corruption, racism and violence intersect in a majority black city. As he takes nonlinear storytelling to an extreme, the show often undercuts itself by toggling back and forth between one too many characters, perspectives and timelines.

There are moments when you are not sure whos when and where. Once you get on its wavelength, the show rewards your patience.

The chief investigation is led by the police corruption task force made up of federal prosecutor Leo Wise (Lucas Van Engen), FBI agent Erika Jensen (Dagmara Domiczyk) and BPD officer John Sieracki (Don Harvey). We follow the trio right from the beginning of their investigation to their interrogation of the arrested GTTF members Momodu Gondo (McKinley Belcher III), Jemell Rayam (Darrell Britt-Gibson), and Maurice Ward (Rob Brown). A secondary investigation takes us to what was the beginning of the end for GTTF.

Detectives David McDougall (David Corenswet) and Scott Kilpatrick (Larry Mitchell), two Narcotics officers, track down a local dealer whose bad batch of heroin is linked to multiple overdoses. On arresting him, they find two tracking devices on his car: one is their own, the other was lent to Gondo. Our proxy in the story is Nicole Steele (Wunmi Mosaku), a Civil Rights attorney conducting an inquiry into the culture of police brutality and corruption in Baltimore. Steeles bafflement, anger and eventual resignation mirrors our own emotional journey across the six episodes.

Darrell Britt-Gibson as Jemell Rayam

With the fallout over the death of Freddie Gray and the rising crime rate, the BPD brought on Sergeant Wayne Jenkins (Jon Bernthal) to lead the GTTF to seize the drugs and guns flooding the streets. As the show reveals, he did to a degree, only not by the book. While he upped the arrest quotas, he also upped the corruption by many levels. Bernthal is an absolute force of nature as Jenkins, a charismatic, hubristic, revolting and delusional man who can justify any moral transgression as a necessary evil. We watch Jenkins steal money and drugs, engage in fatal car chases, and call a colleague to help plant a toy gun after killing an unarmed suspect all without oversight. We hear how squad member Daniel Hersl (Josh Charles) had as many as 50 complaints of brutality on his record, but was allowed to patrol the streets simply because he more than delivered the quota.

Through GTTF member turned homicide detective Sean Suiter (Jamie Hector), we get a glimpse of how Jenkins peer-pressured members of his squad. Suiter died under mysterious circumstances a day before he was scheduled to testify against Jenkins and his gang of criminals. The show leans towards the ruling of the independent review which ruled it to be a death by suicide suggesting Suiter may have taken his own life over the guilt of his brief GTTF involvement. That Jenkins passed the blame onto the dead officer to evade a false evidence charge tells you everything you need to know about him.

Dagmara Domiczyk as Erika Jensen

Indeed, the Jenkins, the Hersls and the Gondos are a symptom of a rot that goes much deeper. The show puts the entire system on trial, not just a bunch of dirty cops. A system that endorses a shoot first, ask questions later policy, offers state-sponsored impunity for police abuse, pushes for results over method, and treats everything, lives included, as a numbers game. In the show, we see mayors and commissioners elected to office outline bold visions, only to resign within months over fraud and tax evasion charges. As there remains a huge gap between policing and public policy in theory and in practice, there also remains a mutual distrust between the community and its government. The failures of policing communities of colour stem from a long history of institutional racism in the US. And the failures of public policy have left the community in an endless cycle of poverty, addiction and violence.

Wunmi Mosaku as Nicole Steele

In one of the shows more telling conversations, Steele meets with Brian Grabler, an ex-cop who became a teacher after becoming disillusioned with the system. Grabler retraces the source of the rot to the so-called war on drugs, a five-decade-old public policy that has only been counterproductive, adding to the violence rather than reducing it. Everything changed when they came up with that expression, The War on Drugs. What an idiotic fucking thing to say. Waging a war against citizens by definition is separating us into two opposing camps. And with the war comes police militarisation. SWAT teams, tactical squads, stop-and-frisk, strip searches, a complete gutting of the Fourth Amendment. And its like were, were fighting terrorists on foreign soil. And you cant just blame the cops. We serve the politicians, who thrive on being tough on crime, he says, before perfectly summing it up in a follow-up conversation, And in a war, you need warriors. In a war, you have enemies. In a war, civilians get hurt and nobody does anything. In a war, you count the bodies and then you call them victories.

All six episodes of We Own This City are now streaming on Disney+ Hotstar.

Prahlad Srihari is a film and music writer based in Bengaluru.

Read all theLatest News,Trending News,Cricket News,Bollywood News,India NewsandEntertainment Newshere. Follow us onFacebook,TwitterandInstagram.

View original post here:
We Own This City review: Spiritual follow-up to The Wire exposes a failure of policing and public policy - Entertainment News , Firstpost - Firstpost

Posted in Fourth Amendment | Comments Off on We Own This City review: Spiritual follow-up to The Wire exposes a failure of policing and public policy – Entertainment News , Firstpost – Firstpost

Release Date Revealed For ‘Star Wars: The Bad Batch’ Season 2 – Inside the Magic

Posted: at 1:57 am

Star Wars Celebration brought plenty of good news for the fanbase where Star Wars TV shows are concerned, whether it was the trailer for the upcoming live-action show Andor (2022), or confirmation that Ahsoka (2023) will be a live-action sequel toStar Wars: Rebels (2014).

But much to the surprise of fans, the first official trailer for Star Wars: The Bad Batch Season 2 was also revealed, which gives us our first look at the return of Clone Force 99 and young Omega (Michelle Ang), who were the main heroes in the first season of the show on Disney + last year.

Related: Jon Favreau Will Usher Emilia Clarkes Return to Star Wars

Check out the official trailer for Star Wars: The Bad Batch Season 2 below:

However, if Streaming Fall 2022 leaves you feeling slightly frustrated, dont worry, because the official release date for the show has finally been revealed by Disney. Star Wars: The Bad Batch Season 2 will be premiering on Disney+ on Wednesday September 28, 2022.

The first season of the show premiered on May 4 last year, known also as Star Wars Day, so by the time the second season lands on Disney+, fans will have waited well over a year to find out where things will go next for Clone Force 99.

Related: Jude Law Will Star In New Official Star Wars Series

Star Wars: The Bad Batch reunited fans with a team of defected clones first introduced in the seventh and final season of beloved animated show Star Wars: The Clone Wars (2008) Echo, Wrecker, Crosshair, Tech, and Hunter, all of whom are voiced by Dee Bradley Baker.

The show follows the team in the wake of Order 66, as the Galactic Empire rises to power. When they learn what plans the Empire has for the galaxy, they decide to abandon their home in the cloning facilities on Kamino, taking with them a young female clone known as Omega.

Related: The Star Wars: Visions Episode That Deserves Its Own Movie

It is revealed that Omega is the sister of Boba Fett like him, she is the direct clone of source clone Jango Fett. However, where the team gains a new member, they lose one in Crosshair, who decides to remain loyal to the Empire, hunting his old teammates at every opportunity.

As per the official Star Wars website, heres the synopsis for Star Wars: The Bad Batch:

Star Wars: The Bad Batchfollows the elite and experimental clones of the Bad Batch (first introduced inStar Wars: The Clone Wars) and their young charge, Omega as they find their way in a rapidly changing galaxy in the immediate aftermath of the Clone War.

Related: A Recap of The Clone Wars and the Prequel Trilogy Before You Watch Obi-Wan Kenobi

The first season ends on a major cliffhanger. Following the destruction of the cloning facility on Kamino, Clone Force 99, along with Omega, go back on the run, while a somewhat conflicted Crosshair chooses to go about his separate ways.

However, we then see Kaminoan female doctor Nala Se (Gwendoline Yeo) taken to a new Imperial cloning facility at an unknown location, which has led to much speculation among Star Wars fans about the possibility of the show becoming connected to the widely hated sequel trilogy.

Related: Star Wars Publicly Defends Obi-Wan Kenobi Star From Racists

As the trailer for Star Wars: The Bad Batch Season 2 reveals, we can expect to see much more action involving Clone Force 99 and Omega, while Emperor Palpatine (Ian McDiarmid) appears to have a bigger presence this time, having only been teased briefly in the first season.

While Fennec Shand (Ming-Na Wen) and Captain Rex (Dee Bradley Baker) make an appearance in the first season, it remains to be seen whether or not other Star Wars characters will show up. Heres to hoping well see Ahsoka Tano (Ashley Eckstein) and Bo-Katan Kryze (Katee Sackhoff).

Related: Which Star Wars TV Shows on Disney+ Are Canon?

Like the first season, Star Wars: The Bad Batch Season 2 will consist of 16 episodes, with a new episode released each week following the premiere on September 28 (although it is not yet known how many episodes will be released on the premiere date).

There are many other Star Wars shows heading to Disney+. Andor will premiere on August 31, while a second season for anime anthology series Star Wars: Visions (2021) was recently confirmed. And given the shows success, Obi-Wan Kenobi (2022) will also get a second season.

Related: Star Wars Series Obi-Wan Kenobi Tops Mandalorian and Marvel

Other upcoming shows include The Mandalorian Season 3 (2023), Ahsoka, Star Wars: Tales of the Jedi (2022), and the recently announced Star Wars: Skeleton Crew (2023), which will be live action and will star A-list actor Jude Law.

Star Wars: The Bad Batch Season 1 is now streaming on Disney+, along with many other canon and non-canon Star Wars TV shows.

Are you looking forward to The Bad Batch Season 2? Let us know in the comments down below!

See the article here:

Release Date Revealed For 'Star Wars: The Bad Batch' Season 2 - Inside the Magic

Posted in Cloning | Comments Off on Release Date Revealed For ‘Star Wars: The Bad Batch’ Season 2 – Inside the Magic

How Close Are We to Resurrecting Extinct Species? – Now. Powered by Northrop Grumman.

Posted: at 1:57 am

Extinction is forever or is it? New advances in DNA technology and cell biology are enabling scientists to help species on the brink of extinction, and will soon allow recently extinct species to be brought back to life.

How close are we to resurrecting extinct species? That all depends on the DNA.

The process of bringing a species back to life is called de-extinction or resurrection biology. This cutting-edge research typically requires nearly complete DNA sequence information from the extinct species. With current technology, scientists can easily obtain this information from living organisms, frozen tissue samples and sometimes even preserved museum specimens.

A bigger challenge is ancient DNA from archaeological sites, samples frozen in permafrost and even some fossils. Nonetheless, scientists have successfully sequenced DNA that is more than half a million years old, as explained in Nature Reviews. Even with new collection technologies, under the best possible conditions, the limit of DNA survival is perhaps 1 million years. The last of the dinosaurs went extinct 65 million years ago, so Jurassic Park likely wont become a reality anytime soon.

The species seriously being considered for de-extinction include woolly mammoths (which went extinct 4,000 years ago), passenger pigeons (last seen around the year 1900), dodo birds, Carolina parakeets, saber-toothed tigers, gastric-brooding frogs, great auks, quaggas and giant tortoises.

As the journal Genes notes, a major goal of de-extinction is to bring back keystone species that played essential roles in shaping their ecosystems and allowed many other species to thrive.

Woolly mammoths once roamed through what we know as Europe, across Asia and into North America, according to Revive & Restore. Mammoths knocked down trees, ate grass and spread seeds with their dung. When they disappeared, biodiversity declined as the lush mammoth steppe was replaced with coniferous taiga forests and mossy tundra, which is now thawing due to climate change and releasing carbon into the atmosphere. This is having a negative impact on the biodiversity that the mammoths unknowingly helped to cultivate. Passenger pigeons played a similarly important role in shaping the deciduous forests of eastern North America.

By returning recently extinct animals to their natural habitats, scientists hope to repair some of the damage that humans have caused and restore entire ecosystems. Comparable efforts from recent times include the successful reintroduction of the California condor to the American west, wolves to Yellowstone National Park, black-footed ferrets to the US high plains, and beavers to much of Europe.

If there are well-preserved cells with intact nuclei, an animal can be cloned. The cells can be grown in a Petri dish under conditions that cause them to behave like embryonic cells instead of mature cells. A cells nucleus contains the genomic DNA, so an intact nucleus can be transferred into a donor egg thats had its nucleus removed. The egg can then be implanted into a surrogate mother and hopefully give rise to a healthy baby that can grow and reproduce naturally. The donor egg and surrogate mother would come from a closely related living species.

The first mammal was cloned from a non-extinct female sheep in 1997 at the University of Edinburgh. Finding the right conditions for cell growth can be a challenge, but the FDA now considers cloning a standard technique for livestock production.

The first extinct species to be cloned was the Pyrean ibex, according to National Geographic. Derived from a frozen skin sample, the cloned goat was born in 2003 and unfortunately died within a few minutes. Later that year, a healthy Javan banteng calf was cloned from a frozen skin sample, as reported by the Washington Post. While the banteng is endangered and not extinct, this success shows that de-extinction through cloning is absolutely possible.

The frozen banteng cells were obtained from the Frozen Zoo, which was started in 1972 by the San Diego Zoo. The Frozen Zoo now contains cryopreserved oocytes, sperm, embryos and other cell types from nearly 1,000 endangered or extinct species. The Frozen Zoo is just one of many frozen cell repositories around the world.

So, how close are we to resurrecting extinct species? Really, really close for species that have frozen cells.

For woolly mammoths and passenger pigeons, there are no well-preserved cells with intact nuclei. However, scientists do have nearly complete DNA sequence information that was acquired by sequencing many small pieces of DNA. Woolly mammoth DNA is 99.4% identical to the DNA of the living Asian elephant, according to the Mammoth Genome Project. Passenger pigeon DNA is 97% identical to the DNA of the living band-tailed pigeon, according to News from Science.

In cases where two species are closely related, many of the DNA sequence differences are inconsequential and dont affect the proteins produced. Accordingly, researchers arent trying to produce an animal thats 100% mammoth; theyre working to modify the DNA of Asian elephant cells to produce hybrid animals that have mammoth-like traits. These traits would include long shaggy fur, thick rolls of insulating body fat, and hemoglobin that can carry oxygen in sub-zero environments. However, the DNA differences that might contribute to mammoth-specific behaviors may be more difficult to identify.

Major advances in gene editing technology, including the CRISPR-Cas9 system, are allowing scientists to make targeted changes to the DNA inside cells. Once a cell is successfully modified, the nucleus would need to be transferred to a donor egg and implanted into a surrogate mother to develop into a healthy baby. Elephants have a two-year gestation period and dont reach sexual maturity for 15 years. Pigeons hatch after 18 days and reach sexual maturity in seven months.

With current technology and research, it could take 5-10 years to bring back a hybrid passenger pigeon, and at least 10 for a hybrid woolly mammoth.

Every day, an estimated 30 to 150 species disappear from the face of our planet. Many species on the brink of extinction could be helped by the same technologies being developed for de-extinction. Cloning can increase numbers, while gene editing technology can be used to reintroduce some of the genetic diversity that was present in museum specimens but lost when natural populations declined.

De-extinction is another example of how technology in this case biotechnology is being used to restore nature and counteract some of the harmful effects of human activity. For these efforts to be successful, humans must also work to prevent and reverse the causes of extinction: habitat destruction, climate change, pollution, overharvesting and more.

Are you interested in science and innovation? We are too. Check out Northrop Grumman career opportunities to see how you can participate in this fascinating time of discovery.

More here:

How Close Are We to Resurrecting Extinct Species? - Now. Powered by Northrop Grumman.

Posted in Cloning | Comments Off on How Close Are We to Resurrecting Extinct Species? – Now. Powered by Northrop Grumman.

The discovery and history of psoriasis: What to know – Medical News Today

Posted: June 3, 2022 at 1:08 pm

Doctor Robert Willan was the first to accurately describe the different types of psoriasis in the early 1800s. In the early 1960s, experts found that psoriasis was an autoimmune disorder, and modern treatment began in the mid-1900s.

In 1809, the English doctor Robert Willan was the first to develop an accurate description of the different types of psoriasis. While doctors learned more about the condition over the years, a pivotal finding emerged in 1963, when E. J. Van Scott found that psoriasis was an autoimmune disorder.

Modern treatment for this condition became available in the mid-1900s, and doctors still use these treatments today. Options include ultraviolet light and medications to reduce inflammation and suppress the immune system.

This article discusses the history and discovery of psoriasis and how treatment has changed.

According to the Psoriasis and Psoriatic Arthritis Alliance, people were aware of psoriasis as early as ancient Greece. Hippocrates wrote some of the first descriptions of skin conditions. However, he classified psoriasis in the same category as leprosy (Hansens disease).

People continued to classify psoriasis in the same category as Hansens disease for several centuries, and as a result, people with psoriasis often experienced stigma and were outcasts from society.

During the Renaissance period, several people wrote books further categorizing skin conditions. Two Italian authors, Girolamo Mercuriale and Bernardino Ramazzini, began to describe different skin conditions, including psoriasis, in their books De Morbius Cutaneis and De Morbis Artificum.

In 1809, the English doctor Robert Willan also categorized skin conditions. He was the first person to provide a description of different types of psoriasis, and he wrote about the progression of the condition.

While Robert Willan was the first person to investigate psoriasis as a separate condition, he still used the term lepra vulgaris, which contributed to people associating psoriasis with leprosy.

In the 1800s, the Austrian physician Ferdinand von Hebra was the first to use modern research techniques to study skin conditions. He also removed lepra from the description of psoriasis.

During this century, French doctors discovered the connection between psoriasis and a form of arthritis called psoriatic arthritis.

Other medical professionals of the time continued to make discoveries that led to later research subcategorizing psoriasis. For example, Australian dermatologist William J. Munro discovered mico-abscesses in the top layer of the skin in people with this condition. Later research would find that these abscesses are part of psoriasis vulgaris, a common form of this condition.

Heinrich Kbner made an important discovery during the 19th century. He found that people with psoriasis may also develop psoriatic lesions in previously unaffected areas that have experienced trauma, such as a cut, burn, or bruise. Doctors still use the Kbner phenomenon as a diagnostic tool today.

The 20th century saw various advancements in the classification of psoriasis and its symptoms.

In 1910, Leo von Zumbusch was the first to describe pustular psoriasis, a rare type of psoriasis that causes pustules, blisters, fever, and fatigue.

In 1926, Dr. Woronoff discovered that people with psoriasis may have a pale ring of skin around healing lesions. This halo, or Woronoff ring, is another diagnostic tool that medical professionals use. The appearance of a Woronoff ring may be a sign that psoriasis lesions are healing.

In 1963, E. J. Van Scott found that people with psoriasis have a rapid turnover of cells, which is a marker of an autoimmune condition. This discovery that psoriasis is an autoimmune condition affected the way doctors treated this condition.

A 1973 paper by John M. Moll and Verna Wright linked psoriasis to psoriatic arthritis. This was one of the first research papers to distinguish psoriatic arthritis from rheumatoid arthritis.

The understanding that psoriasis is an autoinflammatory condition rather than a skin disease has led to advances in treatment. In auto-inflammatory conditions, the immune system attacks healthy tissue and cells in the body.

Within the last decade, discoveries in genetics and molecular science have led to a greater understanding of how psoriasis affects people. Researchers now know that the cause is a complex interaction between immunological, environmental, cellular, and genetic factors.

One of the earliest treatments for psoriasis was coal tar. Medical professionals may still recommend using coal tar as a first-line treatment in cases of mild plaque psoriasis. And they may recommend it in combination with other medications for cases of moderate or severe plaque psoriasis.

In the 1920s, William Goeckerman developed Goeckerman therapy, which combined UVB light with coal tar to treat psoriasis. Doctors still use this treatment today for moderate or severe psoriasis.

Throughout the 1900s, experts created several new treatments, such as:

Biologic drugs are the most recent development in the treatment of psoriasis. These drugs interrupt the immune process of the condition, which can help ease its symptoms. A 2018 study reports that biologics are highly effective and lead to dramatic improvements in 8090% of people with psoriasis.

Healthcare professionals may also prescribe topical and oral retinoids, such as acitretin (Soriatane). Experts are also investigating the effectiveness of Janus kinase (JAK) inhibitors, which healthcare professionals already use in the treatment of rheumatoid arthritis and psoriatic arthritis.

People have been aware of psoriasis for centuries and often grouped this condition with leprosy (Hansens disease). Over time, experts began to recategorize this condition and learn more about how it affects the body, eventually discovering it is an autoimmune condition.

Similarly, treatment has evolved over time to become more effective. There are now several options that a doctor may recommend, many of which were first discovered in the 1900s.

Excerpt from:
The discovery and history of psoriasis: What to know - Medical News Today

Posted in Psoriasis | Comments Off on The discovery and history of psoriasis: What to know – Medical News Today

Psoriasis and stress: The relationship and how to break the cycle – Medical News Today

Posted: at 1:08 pm

Psoriasis can cause stress for someone with the condition due to difficulties managing symptoms, physical discomfort, or feelings of social embarrassment. Conversely, stress can also trigger psoriasis flares. Practicing self-care to improve mental health and reduce stress can help to reduce the chance of stress triggering further flares.

Psoriasis and stress share a symbiotic relationship of sorts, where each can cause and worsen the symptoms of the other.

Psoriasis is a type of immune-mediated disease where the immune system causes inflammation throughout the body.

While many people may associate the condition with scaly patches of skin, it can also cause issues in other areas of the body.

In addition, living with psoriasis can also affect a persons mental health. It may cause a person to feel stress relating to showing their skin, social situations, or caring for the condition.

Stress can then trigger a psoriasis flare or a worsening of symptoms. As a result, people living with psoriasis often benefit from managing both their physical and mental health.

Psoriasis can cause stress, and stress can cause psoriasis symptoms to worsen.

A 2018 review of studies looking at the link between psoriasis and stress notes that anywhere from 3188% of people living with psoriasis report stress as a trigger for their symptoms.

It also noted that, in addition to triggering flares, stress may also trigger the development of the condition itself in people predisposed to developing psoriasis.

How stress influences psoriasis is still not fully understood. According to an older study, one hypothesis, called the neurogenic inflammation hypothesis, states that psoriasis causes the release of neuropeptides, such as substance P (SP) and nerve growth factor (NGF).

These substances then cause local inflammation and result in the formation of psoriasis plaques. The hypothesis notes that stress releases high amounts of SP, which could then trigger the onset of the condition or flares.

When psoriasis plaques occur, it can cause stress for the person. The stress may relate to issues of embarrassment, the challenges of dealing with symptoms, discomfort, or a combination of different emotions.

The National Psoriasis Foundation recommends that all people living with psoriasis take steps to manage their stress as part of their treatment plan. They recommend a person:

According to a 2019 study, there is a link between alcohol intake and an increase in anxiety and depression. Therefore, a person may consider limiting their alcohol consumption to help minimize stress.

Before starting any new exercise programs, a person should talk with a doctor about what activities will be safe for them to perform.

Psoriasis is a lifelong condition characterized by periods of flares and remission. When treating psoriasis, a doctor will often suggest a combination of medications, therapies, mental health support, and lifestyle changes to help keep the condition under control.

Medical treatments may include:

Doctors may also recommend lifestyle changes that help manage symptoms and triggers. The American Academy of Dermatology Association (AAD) recommends a person take some steps to help manage their psoriasis at home:

In addition, a person should take measures to learn and avoid triggers. Triggers can vary from person to person but can include stress and weather changes.

By managing stress, a person may be able to help reduce psoriasis flares.

A person can consider the following general tips for managing stress, including:

Psoriasis triggers can vary from person to person. It is important for an individual to understand their triggers so that they can take steps to avoid them.

Some common triggers of psoriasis include:

Psoriasis and stress share a link both conditions can trigger the other.

Mental health treatment, including lifestyle changes such as physical exercise, can help prevent stress from triggering flares.

It can also help a person cope with the stress and other emotions that often accompany living with psoriasis.

See more here:
Psoriasis and stress: The relationship and how to break the cycle - Medical News Today

Posted in Psoriasis | Comments Off on Psoriasis and stress: The relationship and how to break the cycle – Medical News Today

Findings from Tufts Medical Center in Psoriatic Arthritis Reported (Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial…

Posted: at 1:08 pm

Health Policy and Law Daily

2022 JUN 02 (NewsRx) -- By a News Reporter-Staff News Editor at Health Policy and Law Daily -- Current study results on psoriatic arthritis have been published. According to news reporting out of Boston, Massachusetts, by NewsRx editors, research stated, Specialty medications provide effective treatment with limited adverse effects to patients with psoriasis and psoriatic arthritis; however, variable coverage and high costs often create a barrier to treatment for patients with commercial health insurance.

The news journalists obtained a quote from the research from Tufts Medical Center: We aimed to evaluate coverage of psoriasis and psoriatic arthritis specialty medications by commercial insurance companies. We compiled data regarding specialty drug coverage for psoriasis and psoriatic arthritis using Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) database and analyzed the data for any notable trends. The SPEC database lists coverage decisions for 158 specialty drugs by 17 of the largest US commercial health plans, as well as data regarding the types of evidence cited by these insurance plans when making coverage decisions. Our results showed that insurance plans tend to be more restrictive than the U.S. Food and Drug Association (FDA) label when covering medications for psoriasis and psoriatic arthritis. Furthermore, medications for psoriatic arthritis tended to be less restricted than for psoriasis, and medications were most commonly approved as second line agents for both indications.

According to the news reporters, the research concluded: Our analysis confirms that variability in insurance coverage exists for the indications of psoriasis and psoriatic arthritis.

For more information on this research see: Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial Insurance Companies. Journal of Psoriasis and Psoriatic Arthritis, 2022. The publisher for Journal of Psoriasis and Psoriatic Arthritis is SAGE Publications.

A free version of this journal article is available at https://doi.org/10.1177/24755303221101843.

Our news editors report that additional information may be obtained by contacting Christine Learned, Department of Dermatology, Tufts Medical Center, Boston, MA, United States. Additional authors for this research include Sara Alsukait, Kristin R Fiumara, Melissa Ortega, James D Chambers, David Rosmarin.

ORCID is an identifier for authors and includes bibliographic information. The following is ORCID information for the author of this research: David Rosmarin (http://orcid.org/0000-0003-2786-0708).

(Our reports deliver fact-based news of research and discoveries from around the world.)

The rest is here:
Findings from Tufts Medical Center in Psoriatic Arthritis Reported (Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial...

Posted in Psoriasis | Comments Off on Findings from Tufts Medical Center in Psoriatic Arthritis Reported (Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial…

ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis…

Posted: at 1:08 pm

Data suggest efficacy over standard of care for the treatment of psoriatic arthritis

Izokibep was well-tolerated, having a safety profile consistent with previous studies and the IL-17A inhibitor therapeutic class

Supports hypothesis that izokibep offers greater efficacy with high potency and small size, as well as strategy of evaluating IL-17A inhibition's potential for transformative efficacy across many disease states

LOS ANGELES and SOLNA, Sweden, and SHANGHAI, June 3, 2022 /PRNewswire/ -- ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals today announced data from a 16-week, global, Phase 2 clinical trial of izokibep in 135 patients with psoriatic arthritis (PsA) presented by Frank Behrens, MD, Associate Professor of Medicine, Head of Rheumatology Clinical Research, University Hospital & Deputy Director Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Goethe-University Frankfurt, Germany and a founding member of the Group of Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), during a podium session at the 2022 European Alliance of Associations for Rheumatology (EULAR) Congress in Copenhagen.

The randomized double-blind, placebo-controlled, Phase 2 clinical trial evaluated the safety and efficacy of izokibep dosed 80 mg every two weeks (Q2W) or 40 mg Q2W, versus placebo Q2W, in adult patients with active PsA. The global study assessed various endpoints at 16 weeks including the American College of Rheumatology (ACR) response, the Leeds Enthesitis Index (LEI), the Psoriasis Area and Severity Index (PASI) score and Quality of Life via the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire.

Endpoint

Placebo

Izokibep 80 mg Q2W

Izokibep 40 mg Q2W

ACR50

p-value

13%

52%

0.0006

48%

0.0014

Leeds Enthesitis1

(% LEI=0)

p-value for means

10%

88%

0.0003

63%

0.0095

PASI752

p-value

14%

85%

<0.0001

83%

<0.0001

PsAID

(% beyond MCID)

p-value

12%

41%

0.0017

31%

0.0418

1FAS, observed data for LEI > 0 at baseline N=43 (32%) post-hoc analysis2FAS, observed data for psoriasis BSA 3% at baseline N=74 (55%) post-hoc analysis

Story continues

"Psoriatic arthritis is a painful and debilitating inflammatory disease of the peripheral joints, skin, and nails, and it can also affect the spine," said Professor Behrens. "Furthermore, residual entheseal pain and inflammation,which occurs in up to 60% of patients, is associated with more severe disease, poorer quality of life and is considered one of the most significant unmet needs of psoriatic arthritis patients. The data presented at EULAR demonstrate there is potential opportunity for increased therapeutic efficacy in joints, entheseal pain and inflammation resolution and improved quality of life, all of which would be meaningful for patients living with psoriatic arthritis."

Izokibep was well-tolerated in the study, having a favorable safety profile consistent with that previously observed for izokibep and the IL-17A inhibitor therapeutic class. The most commonly reported AEs were injection site reaction and injection site erythema, the majority of which was mild.

"The improvements demonstrated in arthritis, psoriasis and enthesitis are exciting relative to responses reported for the current standard of care," observed Professor Peter Taylor, Norman Collison chair of musculoskeletal sciences at the University of Oxford. "Combined with theclinically meaningful improvement in disease-specific quality of life and well-tolerated safety profile, izokibep seemspromising for patients living with the painful and debilitating symptoms of psoriatic arthritis, and I am eager to see its continued development for patients."

ACELYRIN holds worldwide rights to izokibep except development and commercialization rights by Inmagene in selected Asian countries, including China, Hong Kong, South Korea, and Taiwan, and excluding Japan. Affibody holds commercialization rights in the Nordic countries.

About izokibep

To date, more than 300 patients many for up to three years have received izokibep, a unique, antibody mimetic, interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of monoclonal antibodies. With high potency and small molecular size, izokibep can reach high drug exposure levels through a single, subcutaneous injection that monoclonal antibodies require IV administration to achieve. Additionally, the small size of izokibep about one tenth the size of a monoclonal antibody enables its potential to reach targeted tissues that may otherwise be inaccessible to the much larger monoclonal antibodies.

About Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory musculoskeletal condition affecting the peripheral joints, the skin (with psoriasis), the nails, and in approximately 30 percent of individuals, the spine. Left under-treated, PsA leads to chronic joint pain, swelling, and damage with a high potential for permanent disability. Psoriatic arthritis pathology is dominated by pro-inflammatory T-helper (Th-17) cells that lead to over expression of IL-17, IL-23, and TNF cytokines.

About ACELYRIN

ACELYRIN, INC. is a Los Angeles area-based biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates and leveraging its expertise to rapidly advance these medicines to patients. For more information, please visit http://www.acelyrin.com

About Affibody AB

Affibody AB is a clinical-stage biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody molecules and Albumod. Affibody is a holding of Patricia Industries. For more information, please visit http://www.affibody.com

About Inmagene Biopharmaceuticals

Inmagene Biopharmaceuticals, with wholly owned subsidiaries in San Diego, Shanghai, Hangzhou, and Wuhan, is a leading biotech company focused on immunology-related therapeutic areas. Believing in "borderless innovation", the Inmagene team integrates efficient resources worldwide to develop drugs for patients globally. Inmagene is operating twelve "Smart Innovation" programs to create and develop novel drug candidates for the global market. For more information, please visit http://www.inmagenebio.com

Disclaimer

This press release contains forward-looking statements. While ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals consider the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by numerous hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

Cision

View original content:https://www.prnewswire.com/news-releases/acelyrin-inc-affibody-ab-and-inmagene-biopharmaceuticals-announce-data-from-global-phase-2-trial-of-izokibep-in-patients-with-psoriatic-arthritis-presented-during-2022-european-alliance-of-associations-for-rheumatology-congress-301560613.html

SOURCE ACELYRIN, INC.

Original post:
ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis...

Posted in Psoriasis | Comments Off on ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis…